Hyloris Pharmaceuticals SA (HYL.BR)

EUR 6.35

(0.05%)

EBITDA Summary of Hyloris Pharmaceuticals SA

Hyloris Pharmaceuticals SA's latest annual EBITDA in 2023 was -14.98 Million EUR , down -72.37% from previous year.
Hyloris Pharmaceuticals SA's latest quarterly EBITDA in 2023 FY was N/A , down -72.37% from previous quarter.
Hyloris Pharmaceuticals SA reported an annual EBITDA of -11.43 Million EUR in 2022, up 3.44% from previous year.
Hyloris Pharmaceuticals SA reported an annual EBITDA of -10.78 Million EUR in 2021, down -86.62% from previous year.
Hyloris Pharmaceuticals SA reported a quarterly EBITDA of -4.37 Million EUR for 2023 Q3, down -27.55% from previous quarter.
Hyloris Pharmaceuticals SA reported a quarterly EBITDA of -3.42 Million EUR for 2023 Q1, down -2.74% from previous quarter.

Annual EBITDA Chart of Hyloris Pharmaceuticals SA (2023 - 2017)

Historical Annual EBITDA of Hyloris Pharmaceuticals SA (2023 - 2017)

Year	EBITDA	EBITDA Growth
2023	-14.98 Million EUR	-72.37%
2022	-11.43 Million EUR	3.44%
2021	-10.78 Million EUR	-86.62%
2020	-6.17 Million EUR	-174.77%
2019	-5.26 Million EUR	63.33%
2018	-5.62 Million EUR	-57.64%
2017	-3.57 Million EUR	0.0%

Year	EBITDA	EBITDA Growth
2023 Q2	-3.42 Million EUR	0.0%
2023 Q3	-4.37 Million EUR	-27.55%
2023 Q1	-3.42 Million EUR	-2.74%
2023 FY	- EUR	-72.37%
2023 Q4	-4.38 Million EUR	-0.42%
2022 Q2	-4.95 Million EUR	-108.23%
2022 FY	- EUR	3.44%
2022 Q4	-3.33 Million EUR	0.0%
2022 Q3	-3.33 Million EUR	32.75%
2022 Q1	-2.38 Million EUR	5.01%
2021 FY	- EUR	-86.62%
2021 Q4	-2.5 Million EUR	39.11%
2021 Q3	-4.11 Million EUR	-75.49%
2021 Q2	-2.34 Million EUR	-130.11%
2021 Q1	-1.01 Million EUR	-43.69%
2020 Q2	-1.65 Million EUR	-25.23%
2020 FY	- EUR	-174.77%
2020 Q4	-709.5 Thousand EUR	0.0%
2020 Q1	-1.32 Million EUR	-159.35%
2020 Q3	-709.5 Thousand EUR	57.21%
2019 Q2	-526 Thousand EUR	3.31%
2019 Q3	-510.49 Thousand EUR	2.95%
2019 Q1	-544 Thousand EUR	0.0%
2019 FY	- EUR	63.33%
2019 Q4	-510.49 Thousand EUR	0.0%
2018 FY	- EUR	-57.64%
2017 FY	- EUR	0.0%

Peer EBITDA Comparison of Hyloris Pharmaceuticals SA

Name	EBITDA	EBITDA Difference
Nicox S.A.	-16.23 Million EUR	7.747%
European Medical Solutions	59 Thousand EUR	25489.831%
FERMENTALG	-10.51 Million EUR	-42.531%
argenx SE	-199.5 Million EUR	92.491%
BioSenic S.A.	-6.79 Million EUR	-120.424%
Celyad Oncology SA	-7.76 Million EUR	-92.967%
Onward Medical N.V.	-35.23 Million EUR	57.484%
Oxurion NV	-16.72 Million EUR	10.455%
PHAXIAM Therapeutics S.A.	-22.93 Million EUR	34.671%
Financière de Tubize SA	184.57 Thousand EUR	8216.118%
UCB SA	1.26 Billion EUR	101.18%